Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis

IF 5.1 2区医学 Q1 HEMATOLOGY

British Journal of Haematology Pub Date : 2024-07-23 DOI:10.1111/bjh.19670

Barbora Weinbergerová, Jiří Mayer, Tomáš Kabut, Wolfgang R. Sperr, Jana Števková, Anna Jonášová, Martin Čerňan, Susanne Herndlhofer, Iveta Oravcová, Jiří Šrámek, Jan Novák, Radka Štěpánová, Tomáš Szotkowski, Luboš Drgoňa, Pavel Žák, Peter Valent

{"title":"Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis","authors":"Barbora Weinbergerová, Jiří Mayer, Tomáš Kabut, Wolfgang R. Sperr, Jana Števková, Anna Jonášová, Martin Čerňan, Susanne Herndlhofer, Iveta Oravcová, Jiří Šrámek, Jan Novák, Radka Štěpánová, Tomáš Szotkowski, Luboš Drgoňa, Pavel Žák, Peter Valent","doi":"10.1111/bjh.19670","DOIUrl":null,"url":null,"abstract":"Our observational study analysed fungal infection frequency within cohorts with versus without antifungal prophylaxis (AFP) among newly diagnosed first-line venetoclax and azacitidine (VEN + AZA)-treated acute myeloid leukaemias in Czech, Austrian and Slovak haematology centres. Among 186 patients, 85 (46%) received antifungal prophylaxis, while 101 (54%) received no prophylaxis. Fungal infections occurred in 1/85 patients with prophylaxis (1%) and 5/101 patients without prophylaxis (5%) (p = 0.222). No significant difference was recorded between cohorts with and without AFP in terms of death rate (p = 0.296) and overall survival (p = 0.844). In conclusion, most infections were not severe, developing during the first treatment-cycle and did not affect patients' overall outcome.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"205 5","pages":"1746-1750"},"PeriodicalIF":5.1000,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.19670","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Haematology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bjh.19670","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Our observational study analysed fungal infection frequency within cohorts with versus without antifungal prophylaxis (AFP) among newly diagnosed first-line venetoclax and azacitidine (VEN + AZA)-treated acute myeloid leukaemias in Czech, Austrian and Slovak haematology centres. Among 186 patients, 85 (46%) received antifungal prophylaxis, while 101 (54%) received no prophylaxis. Fungal infections occurred in 1/85 patients with prophylaxis (1%) and 5/101 patients without prophylaxis (5%) (p = 0.222). No significant difference was recorded between cohorts with and without AFP in terms of death rate (p = 0.296) and overall survival (p = 0.844). In conclusion, most infections were not severe, developing during the first treatment-cycle and did not affect patients' overall outcome.

查看原文本刊更多论文

新确诊的急性髓性白血病患者接受文尼他克加阿扎胞苷治疗（无论有无抗真菌预防）时的真菌感染频率。

我们的观察性研究分析了捷克、奥地利和斯洛伐克血液学中心新确诊的一线文尼他克和阿扎胞苷（VEN + AZA）治疗急性髓性白血病患者中，接受与未接受抗真菌预防（AFP）治疗的队列中真菌感染的频率。在186名患者中，85人（46%）接受了抗真菌预防治疗，101人（54%）未接受预防治疗。85名接受预防治疗的患者中有1人（1%）发生真菌感染，101名未接受预防治疗的患者中有5人（5%）发生真菌感染（P = 0.222）。在死亡率（p = 0.296）和总生存率（p = 0.844）方面，使用和未使用 AFP 的队列之间没有明显差异。总之，大多数感染并不严重，发生在第一个治疗周期，不会影响患者的总体预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

British Journal of Haematology 医学-血液学

CiteScore

8.60

自引率

4.60%

发文量

565

审稿时长

1 months

期刊介绍： The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.